Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Multicenter Trial to Evaluate the Efficacy and Safety of the Following Treatment Squeme:Ciclophosphamide, Vincristine, Lyposomal Doxorrubicine, Myocet and Prednisone,Combined With Rituximab in First Line Treatment for Patients With Aggresive No Hodgkin B Lymphoma and Cardiovascular Risk

NCT00849355 is registered in ClinicalTrials.gov with Asociacion Doctor Peset Para el Estudio de la Hematología as lead sponsor.

NCT NCT00849355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00849355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Multicenter Trial to Evaluate the Efficacy and Safety of the Following Treatment Squeme:Ciclophosphamide, Vincristine, Lyposomal Doxorrubicine, Myocet and Prednisone,Combined With Rituximab in First Line Treatment for Patients With Aggresive No Hodgkin B Lymphoma and Cardiovascular Risk
Lead sponsor
Asociacion Doctor Peset Para el Estudio de la Hematología
Phase
Phase 2
Overall status
Unknown status
Start date
August 31, 2008
Completion date
November 30, 2010
Enrollment
44 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

no hodgkin b lymphoma